{"id":"tislelizumab-cisplatin-gemcitabine","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Weight loss"},{"rate":"5-20%","effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tislelizumab works by binding to the PD-1 receptor on T cells, preventing the PD-L1 ligand from binding and thereby inhibiting the immune checkpoint. Cisplatin works by forming platinum-DNA adducts that interfere with DNA replication and transcription, leading to cell death. Gemcitabine works by being incorporated into DNA, causing DNA strand breaks and inhibiting DNA synthesis, leading to cell death.","oneSentence":"Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, Cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication, and Gemcitabine is a nucleoside analog that inhibits DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:03.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, metastatic or locally advanced"},{"name":"Esophageal squamous cell carcinoma, metastatic"},{"name":"Urothelial carcinoma, metastatic"},{"name":"Gastric cancer, metastatic"},{"name":"Colorectal cancer, metastatic"},{"name":"Head and neck squamous cell carcinoma, metastatic"},{"name":"Triple-negative breast cancer, metastatic"},{"name":"Cervical cancer, recurrent or metastatic"},{"name":"Hepatocellular carcinoma, advanced"},{"name":"Non-small cell lung cancer, locally advanced or metastatic"}]},"trialDetails":[{"nctId":"NCT07174947","phase":"PHASE2","title":"SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-01","conditions":"Hepatobiliary Malignancy, Fluoxetine, Anxiety Disorders","enrollment":240},{"nctId":"NCT05502250","phase":"PHASE2","title":"Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2023-07-14","conditions":"Hodgkin Lymphoma","enrollment":75},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT07373990","phase":"PHASE3","title":"Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-15","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":418},{"nctId":"NCT03967977","phase":"PHASE3","title":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2019-05-29","conditions":"Urothelial Carcinoma","enrollment":420},{"nctId":"NCT07353294","phase":"PHASE1","title":"Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Bladder Urothelial Carcinoma, Lymph Node Metastasis","enrollment":12},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT05516914","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2022-09-01","conditions":"Malignant Tumors","enrollment":490},{"nctId":"NCT07248696","phase":"NA","title":"Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":32},{"nctId":"NCT06893380","phase":"","title":"Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"CHA University","startDate":"2024-10-01","conditions":"Locally Advanced Biliary Tract Cancers, Metastatic Biliary Tract Cancers","enrollment":61},{"nctId":"NCT06177301","phase":"PHASE3","title":"Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Nasopharyngeal Carcinoma","enrollment":266},{"nctId":"NCT07119996","phase":"PHASE1","title":"Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":12},{"nctId":"NCT04570410","phase":"PHASE2","title":"Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-12-01","conditions":"Bladder Urothelial Carcinoma","enrollment":30},{"nctId":"NCT07099547","phase":"PHASE2","title":"Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-09","conditions":"Biliary Tract Carcinoma","enrollment":60},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT04833257","phase":"PHASE2","title":"Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-04-14","conditions":"Nasopharyngeal Carcinoma","enrollment":63},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT06916494","phase":"PHASE1","title":"Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-05-01","conditions":"Muscle Invasive Bladder Cancer","enrollment":10},{"nctId":"NCT06903273","phase":"PHASE2","title":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Biliary Tract Cancer (BTC)","enrollment":35},{"nctId":"NCT06364904","phase":"PHASE3","title":"A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-10","conditions":"Bladder Cancer","enrollment":210},{"nctId":"NCT05532059","phase":"PHASE2","title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-31","conditions":"Advanced Cholangiocarcinoma","enrollment":100},{"nctId":"NCT05823311","phase":"PHASE3","title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-01","conditions":"Advanced Cholangiocarcinoma","enrollment":80},{"nctId":"NCT03924986","phase":"PHASE3","title":"Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-03-27","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer","enrollment":263},{"nctId":"NCT06696742","phase":"PHASE2","title":"PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-02-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":60},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT03432598","phase":"PHASE2","title":"Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-08-24","conditions":"Locally Advanced Lung Cancer; Metastatic Lung Cancer","enrollment":54},{"nctId":"NCT06383780","phase":"PHASE3","title":"Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.","status":"RECRUITING","sponsor":"XIANG YANQUN","startDate":"2024-05-15","conditions":"Nasopharyngeal Carcinoma","enrollment":90},{"nctId":"NCT05531123","phase":"PHASE2","title":"Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-09-10","conditions":"Bladder Cancer","enrollment":30},{"nctId":"NCT05211232","phase":"PHASE3","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06-10","conditions":"Nasopharyngeal Carcinoma","enrollment":450},{"nctId":"NCT06331845","phase":"PHASE2","title":"Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-05-01","conditions":"Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy","enrollment":39},{"nctId":"NCT05023109","phase":"PHASE2","title":"GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-02-01","conditions":"Biliary Tract Carcinoma","enrollment":45},{"nctId":"NCT05401279","phase":"PHASE2","title":"Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-06-01","conditions":"Urothelial Carcinoma Bladder, PD-1 Inhibitor","enrollment":20},{"nctId":"NCT05448885","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-09-01","conditions":"Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT04921995","phase":"PHASE2","title":"Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-04-15","conditions":"Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect","enrollment":40},{"nctId":"NCT05019677","phase":"PHASE2","title":"GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC","status":"WITHDRAWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":""},{"nctId":"NCT04909775","phase":"PHASE2","title":"Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-07","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT04672317","phase":"PHASE2","title":"Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-12-10","conditions":"Neoadjuvant Therapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tislelizumab, Cisplatin, Gemcitabine","genericName":"Tislelizumab, Cisplatin, Gemcitabine","companyName":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","companyId":"sun-yat-sen-memorial-hospital-of-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a PD-1 inhibitor monoclonal antibody that blocks the PD-1 receptor, Cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication, and Gemcitabine is a nucleoside analog that inhibits DNA synthesis. Used for Non-small cell lung cancer, metastatic or locally advanced, Esophageal squamous cell carcinoma, metastatic, Urothelial carcinoma, metastatic.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}